Onur YAZICI, Fisun KARADAĞ, Emel CEYLAN, Şule Taş GÜLEN, Hatice arzu UÇAR, Mehmet POLATLI

The Role of Serum Angiotensin Converting Enzyme for Predicting Pulmonary Parenchymal and Extrapulmonary Involvement of Sarcoidosis

ABSTRACT INTRODUCTION: The clinical characteristics and course of sarcoidosis vary according to the age of onset, duration, stage, and extent of the disease. Biomarkers that can predict clinical characteristics and course will provide convenience in disease management. We aimed to determine relationships of hematologic and biochemical parameters with the stage and extent of the disease. METHODS: The charts of sarcoidosis patients between 2013 and 2018 were retrospectively investigated. Demographic data, clinical findings at the time of diagnosis, stage, and extrapulmonary involvement were recorded together with complete blood count, erythrocyte sedimentation rate, serum C-reactive protein, calcium, and angiotensin converting enzyme (ACE) levels. Patients were classified according to the presence of pulmonary parenchymal and extrapulmonary involvement. Stage-1 patients with no pulmonary parenchymal involvement were in Group 1, and stage-2 and stage-3 patients with pulmonary parenchymal involvement in Group 2. RESULTS: Of 121 sarcoidosis patients, 30 (24.8%) were male, 91 (75.2%) female. The average age was 50.71±11.76 years. 59 (48.8%) patients were in Group 1, and 62 (51.2%) in Group 2. Pulmonary involvement was present only in 71 (58.7%) patients. Extrapulmonary and pulmonary involvement was present in 50 (41.3%) patients. Most common extrapulmonary involvement was erythema nodosum (15.7%). Serum ACE level was higher in Group 2 than Group 1 (p=0.027) and in cases with pulmonary and extrapulmonary involvement both than those with pulmonary involvement only (p=0.045). No significant deviations were found between the groups regarding other laboratory parameters.

Sarkoidozda Pulmoner Parankimal ve Ekstrapulmoner Tulumu Belirlemede Serum Anjiyotensin Konverting Enzimin Rolü

ÖZ GİRİŞ ve AMAÇ: Sarkoidoz günümüzde halen etiyolojisi bilinmeyen bir hastalıktır. Klinik tablo ve seyir hastalığın başlangıç yaşına, süresine, evresine ve yaygınlığına bağlı olarak değişmektedir. Klinik tabloyu ve seyri öngörebilecek biyomarkerların kullanılması hastalığın yönetiminde kolaylık sağlayacaktır. Çalışmamızda hematolojik ve biyokimyasal parametrelerle hastalığın evre ve yaygınlığı arasındaki ilişkiyi belirlemeyi amaçladık. YÖNTEM ve GEREÇLER: 2013-2018 yılları arasında kliniğimizde sarkoidoz tanısı konulan hastaların dosyaları retrospektif olarak incelendi. Hastaların demografik verileri, tanı sırasındaki klinik bulguları, evreleri, ekstrapulmoner tutulum olup olmadığı ve hemogram, eritrosit sedimentasyon hızı (ESR), C reaktif protein (CRP), serum kalsiyum (Ca) ve anjiotensin konverting enzim (ACE) düzeylerini içeren laboratuvar parametreleri kaydedildi. Hastalar akciğer parankim tutulumu ve ekstrapulmoner tutulumu olup olmamasına göre sınıflandırıldı. Akciğer parankim tutulumu olmayan evre 1 hastalar grup 1 ve akciğer parankim tutulumu olan evre 2 ve 3 hastalar grup 2 olarak sınıflandırıldı. BULGULAR: Belirlenen tarihler arasında 121 sarkoidoz hastasının verilerine ulaşıldı. Hastaların 30 (%24.8)’u erkek, 91 (%75.2)’i kadın ve yaş ortalaması 50.71±11.76 idi. Grup 1’de 59 (%48,8) ve grup 2’de 62 (%51,2) olgu vardı. Hastaların 71 (%58,9)’de sadece akciğer tutulumu varken 50 (%41.3)’sinde akciğer ve akciğer dışı organ tutulumu birlikte vardı. Akciğer dışı organ tutulumu en sık eritema nodozum (EN)’du (%15,7). Grup 2 olgularda serum ACE değeri grup 1’den daha yüksekti (p =0,027). Akciğer ve akciğer dışı tutulumu olan olgularda serum ACE düzeyi akciğer dışı tutulum olmayanlara göre daha yüksekti (p =0,045). Bakılan diğer laboratuvar parametreleri gruplar arasında farklı değildi

PDF

___

1.Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:149-73.

2.Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-55.

3.Rybicki BA, Major M, Popovich J, Jr., Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997;145:234-41.

4.Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol 2012;66:699 e1-18.

5.Musellim B, Kumbasar OO, Ongen G, Cetinkaya E, Turker H, Uzaslan E, et al. Epidemiological features of Turkish patients with sarcoidosis. Respir Med 2009;103:907-12.

6.Lynch JP, 3rd, Ma YL, Koss MN, White ES. Pulmonary sarcoidosis. Semin Respir Crit Care Med 2007;28:53-74.

7.Coker RK. Management strategies for pulmonary sarcoidosis. Ther Clin Risk Manag 2009;5:575-84.

8.Costabel U, Ohshimo S, Guzman J. Diagnosis of sarcoidosis. Curr Opin Pulm Med 2008;14:455- 61. 9. Yeager H, Rossman MD, Baughman RP, Teirstein AS, Judson MA, Rabin DL, et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:147-53.

9.Baughman RP, Lower EE. Treatment of Sarcoidosis. Clin Rev Allergy Immunol 2015;49:79- 92.

10.Winterbauer RH, Lammert J, Selland M, Wu R, Corley D, Springmeyer SC. Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest 1993;104:352- 61.

11.Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. General considerations for lung function testing. Eur Respir J 2005;26:153-61.

12.Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J 1961;2:1165-72.

13.Liu Y, Qiu L, Wang Y, Aimurola H, Zhao Y, Li S, et al. The Circulating Treg/Th17 Cell Ratio Is Correlated with Relapse and Treatment Response in Pulmonary Sarcoidosis Patients after Corticosteroid Withdrawal. PLoS One 2016;11:e0148207.

14.Denning DW. Sarcoidosis and aspergillosis: a tough combination. Eur Respir J 2017;49.

15.Lammi L, Kinnula V, Lahde S, Risteli J, Paakko P, Lakari E, et al. Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. Eur Respir J 1997;10:2725- 30.

16.Yalnız E, Kömürcüoğlu A, Polat Erbay G, Utkaner G, Yüksel M. Sarkoidozda klinik, radyolojik, laboratuvarla ilgili parametreler ve tanı yöntemleri. Toraks Dergisi 2003;4:48-52.

17.Consensus conference: activity of sarcoidosis. Third WASOG meeting, Los Angeles, USA, September 8-11, 1993. Eur Respir J 1994;7:624-7.

18.Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357:2153- 65.

19.Muthuswamy PP, Lopez-Majano V, Ranginwala M, Trainor WD. Serum angiotensinconverting enzyme (SACE) activity as an indicator of total body granuloma load and prognosis in sarcoidosis. Sarcoidosis 1987;4:142-8.

20.Studdy PR, James DG. The specificity and sensitivity of serum angiotensin converting enzyme in sarcoidosis and other diseases. Experience in twelve centers in six different countries. In: Chretien J, Marsac J, Saltiel JC, editors. Sarcoidosis and other granulomatous disorders. Paris: Pergamon Press, 1983:332-44 .

21.Pietinalho A, Ohmichi M, Lofroos AB, Hiraga Y, Selroos O. The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan. A comparative five-year study of biopsy-proven cases. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:158-66.

22.Popevic S, Sumarac Z, Jovanovic D, Babic D, Stjepanovic M, Jovicic S, et al. Verifying Sarcoidosis Activity: Chitotriosidase versus ACE in Sarcoidosis - a Case-control Study. J Med Biochem 2016;35:390-400.

23.Sahan N, Ermis H, Karataslı M. Clinical features and diagnostic methods of sarcoidosis according to stages: Evaluation of 55 cases. Solunum 2008;10:89-96.

24.Lieberman J, Schleissner LA, Nosal A, Sastre A, Mishkin FS. Clinical correlations of serum angiotensin-converting enzyme (ACE) in sarcoidosis. A longitudinal study of serum ACE, 67gallium scans, chest roentgenograms, and pulmonary function. Chest 1983;84:522-8.

25.DeRemee RA, Rohrbach MS. Serum angiotensin-converting enzyme activity in evaluating the clinical course of sarcoidosis. Ann Intern Med 1980;92:361-5.

26.Kruit A, Grutters JC, Gerritsen WB, Kos S, Wodzig WK, van den Bosch JM, et al. ACE I/Dcorrected Z-scores to identify normal and elevated ACE activity in sarcoidosis. Respir Med 2007;101:510-5.

27.Rao DA, Dellaripa PF. Extrapulmonary manifestations of sarcoidosis. Rheum Dis Clin North Am 2013;39:277-97.

28.Judson MA. Extrapulmonary sarcoidosis. Semin Respir Crit Care Med 2007;28:83- 101.

29.Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Jr., Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885-9.

30.Okumus G, Musellim B, Cetinkaya E, Turker H, Uzaslan E, Yenturk E, et al. Extrapulmonary involvement in patients with sarcoidosis in Turkey. Respirology 2011;16:446-50.

31.Li CW, Tao RJ, Zou DF, Li MH, Xu X, Cao WJ. Pulmonary sarcoidosis with and without extrapulmonary involvement: a cross-sectional and observational study in China. BMJ Open 2018;8:e018865.

32.Zurkova M, Kolek V, Tomankova T, Kriegova E. Extrapulmonary involvement in patients with sarcoidosis and comparison of routine laboratory and clinical data to pulmonary involvement. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014;158:613-20.

33.Yasar Z, Ozgul MA, Cetinkaya E, Kargi A, Gul S, Talay F, et al. Angiotensinconverting Enzyme as a Predictor of Extrathoracic Involvement of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2016;32:318-24.

34.Gvozdenovic BS, Mihailovic-Vucinic V, IlicDudvarski A, Zugic V, Judson MA. Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respir Med 2008;102:1636-42.

35.Rodrigues SC, Rocha NA, Lima MS, Arakaki JS, Coletta EN, Ferreira RG, et al. Factor analysis of sarcoidosis phenotypes at two referral centers in Brazil. Sarcoidosis Vasc Diffuse Lung Dis 2011;28:34-43.

36.Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H, Jr. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:75- 86.

37.O'Neill JH, Jr. The differential diagnosis of erythema nodosum. Del Med J 1991;63:683-9.